FOOD AND LIFESTYLE Dose adjustment might be necessary if
smoking started or stopped during treatment with ropinirole.
▶ Amisulpride is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 9
▶ Antiarrhythmics (dronedarone) are predicted to increase the
exposure to bromocriptine.rTheoretical
▶ Antiarrhythmics (dronedarone) are predicted to increase the
concentration of cabergoline.rAnecdotal
▶ Antifungals, azoles (fluconazole, isavuconazole, itraconazole,
ketoconazole, posaconazole, voriconazole) are predicted to
increase the concentration of cabergoline.oAnecdotal
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure to
▶ Antifungals, azoles (isavuconazole) are predicted to increase the
exposure to pramipexole. Adjust dose.oStudy
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole)
increase the exposure to bromocriptine.rStudy
▶ Aprepitant is predicted to increase the exposure to
▶ Aprepitant is predicted to increase the concentration of
▶ Aripiprazole is predicted to decrease the effects of dopamine
receptor agonists.oTheoretical → Also see TABLE 8 p. 1376
▶ Asenapine is predicted to decrease the effects of dopamine
receptor agonists. Adjust dose.oTheoretical → Also see
▶ Benperidol is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
▶ Bupropion increases the risk of side-effects when given with
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to bromocriptine.rTheoretical →
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
Anecdotal → Also see TABLE 8 p. 1376
cabergoline.o ▶ Clozapine is predicted to decrease the effects of dopamine
receptor agonists.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 10 p. 1377
increases the exposure to bromocriptine.r
▶ Cobicistat is predicted to increase the concentration of
▶ Combined hormonal contraceptives are predicted to increase
the exposure to ropinirole. Adjust dose.oStudy
▶ Crizotinib is predicted to increase the exposure to
▶ Crizotinib is predicted to increase the concentration of
▶ Dolutegravir is predicted to increase the exposure to
pramipexole. Adjust dose.oStudy
▶ Domperidone is predicted to decrease the prolactin-lowering
effect of dopamine receptor agonists (bromocriptine,
▶ Dopamine receptor agonists (cabergoline) are predicted to
increase the risk of ergotism when given with dopamine
receptor agonists (bromocriptine). Avoid.oTheoretical →
▶ Dopamine receptor agonists (bromocriptine, cabergoline) are
predicted to increase the risk of ergotism when given with
Theoretical → Also see TABLE 8
. Avoid.o ▶ Dopamine receptor agonists (amantadine) are predicted to
increase the exposure to dopamine receptor agonists
(pramipexole). Adjust dose.oTheoretical → Also see
▶ Droperidol is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377
▶ Ergometrine is predicted to increase the risk of ergotism when
given with dopamine receptor agonists (cabergoline, pergolide).
1444 Dolutegravir — Dopamine receptor agonists BNF 78
▶ Ergotamine is predicted to increase the risk of ergotism when
given with dopamine receptor agonists (bromocriptine,
cabergoline). Avoid.oTheoretical
▶ Ergotamine is predicted to increase the risk of ergotism when
given with pergolide.oTheoretical
▶ Flupentixol is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
▶ Apomorphine is predicted to increase the risk of severe
hypotension when given with granisetron.rTheoretical
▶ H2 receptor antagonists (cimetidine) are predicted to increase
the exposure to pramipexole. Adjust dose.oStudy
▶ Haloperidol is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377 → Also see TABLE 10 p. 1377
increase the exposure to bromocriptine.
▶ HIV-protease inhibitors are predicted to increase the
concentration of cabergoline.oAnecdotal
▶ Hormone replacement therapy decreases the clearance of
ropinirole. Monitor and adjust dose.oStudy
▶ Idelalisib increases the exposure to bromocriptine.rStudy
▶ Idelalisib is predicted to increase the concentration of
▶ Imatinib is predicted to increase the exposure to
▶ Imatinib is predicted to increase the concentration of
▶ Loxapine is predicted to decrease the effects of dopamine
receptor agonists.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 10 p. 1377
▶ Macrolides (clarithromycin) increase the exposure to
▶ Macrolides (clarithromycin, erythromycin) are predicted to
increase the concentration of cabergoline. Avoid.rStudy
▶ Macrolides (erythromycin) are predicted to increase the
exposure to bromocriptine.rTheoretical
▶ Amantadine increases the risk of CNS toxicity when given with
memantine. Use with caution or avoid.rTheoretical
▶ Memantine is predicted to increase the effects of dopamine
receptor agonists (apomorphine, bromocriptine, cabergoline,
pergolide, pramipexole, quinagolide, ropinirole, rotigotine)
▶ Metoclopramide is predicted to decrease the effects of
dopamine receptor agonists (apomorphine, bromocriptine,
cabergoline, pergolide, pramipexole, quinagolide, ropinirole,
▶ Mexiletine is predicted to increase the exposure to ropinirole.
▶ Netupitant is predicted to increase the exposure to
▶ Netupitant is predicted to increase the concentration of
▶ Nilotinib is predicted to increase the exposure to
▶ Nilotinib is predicted to increase the concentration of
▶ Olanzapine is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
▶ Apomorphine increases the risk of severe hypotension when
given with ondansetron. Avoid.rStudy → Also see TABLE 9
▶ Paliperidone is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377
▶ Apomorphine is predicted to increase the risk of severe
hypotension when given with palonosetron.rTheoretical
▶ Phenothiazines are predicted to decrease the effects of
dopamine receptor agonists. Avoid.oTheoretical → Also
see TABLE 8 p. 1376 → Also see TABLE 9 p. 1377 → Also see TABLE 10
▶ Pimozide is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377 → Also see TABLE 10 p. 1377
▶ Quetiapine is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
▶ Quinolones (ciprofloxacin) are predicted to increase the
exposure to ropinirole. Adjust dose.oStudy
▶ Ranolazine is predicted to increase the exposure to
pramipexole. Adjust dose.oStudy
▶ Risperidone is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377
▶ SSRIs (fluvoxamine) are predicted to increase the exposure to
ropinirole. Adjust dose.oStudy
▶ Sulpiride is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377
▶ Sympathomimetics, vasoconstrictor (isometheptene) potentially
increase the risk of side-effects when given with
bromocriptine. Avoid.rAnecdotal
▶ Trimethoprim is predicted to increase the exposure to
pramipexole. Adjust dose.oStudy
▶ Vandetanib is predicted to increase the exposure to
pramipexole. Adjust dose.oStudy
▶ Zuclopenthixol is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
▶ Antiepileptics (oxcarbazepine) are predicted to decrease the
exposure to doravirine. Avoid.rTheoretical
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to doravirine.nStudy
▶ Bosentan is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
▶ Cobicistat is predicted to increase the exposure to doravirine.
▶ Dabrafenib is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
▶ Efavirenz is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
▶ Enzalutamide is predicted to decrease the exposure to
▶ HIV-protease inhibitors are predicted to increase the exposure
▶ Idelalisib is predicted to increase the exposure to doravirine.
▶ Lumacaftor is predicted to decrease the exposure to
doravirine. Avoid.rTheoretical
▶ Macrolides (clarithromycin) are predicted to increase the
▶ Mitotane is predicted to decrease the exposure to doravirine.
▶ Modafinil is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
▶ Nevirapine is predicted to decrease the exposure to doravirine.
Avoid or adjust doravirine dose, p. 644.rTheoretical
▶ Rifabutin moderately decreases the exposure to doravirine.
Adjust doravirine dose, p. 644.rStudy
▶ Rifampicin is predicted to decrease the exposure to doravirine.
▶ Doravirine is predicted to decrease the exposure to sirolimus.
sirolimus concentration and adjust dose, p. 840.
▶ St John’s Wort is predicted to decrease the exposure to
doravirine. Avoid.rTheoretical
▶ Doravirine is predicted to decrease the exposure to tacrolimus.
tacrolimus concentration and adjust dose, p. 841.
▶ Telotristat ethyl is predicted to decrease the exposure to
. Avoid or adjust doravirine dose, p. 644.r
BNF 78 Dopamine receptor agonists — Doravirine 1445
ROUTE-SPECIFIC INFORMATION Since systemic absorption can
follow topical application, the possibility of interactions
Dosulepin → see tricyclic antidepressants
▶ Aminophylline increases the risk of agitation when given with
▶ Monoamine-oxidase A and B inhibitors, irreversible are
predicted to increase the effects of
doxapram.o ▶ Theophylline increases the risk of agitation when given with
Doxazosin → see alpha blockers
Doxepin → see tricyclic antidepressants
Doxorubicin → see anthracyclines
Doxycycline → see tetracyclines
Doxylamine → see antihistamines, sedating
Dronedarone → see antiarrhythmics
▶ Droperidol is predicted to decrease the effects of dopamine
receptor agonists. Avoid.oTheoretical → Also see TABLE 8
p. 1376 → Also see TABLE 9 p. 1377
▶ Droperidol is predicted to decrease the effects of guanethidine.
Monitor and adjust dose.oTheoretical → Also see TABLE 8
▶ Droperidol decreases the effects of levodopa.rStudy →
Drospirenone → see TABLE 16 p. 1379 (increased serum potassium)
▶ Antifungals, azoles (ketoconazole) moderately increase the
exposure to drospirenone.rStudy
Dulaglutide → see TABLE 14 p. 1378 (antidiabetic drugs)
Duloxetine → see TABLE 18 p. 1379 (hyponatraemia), TABLE 13 p. 1378
(serotonin syndrome), TABLE 4 p. 1375 (antiplatelet effects)
▶ Antiepileptics (phenytoin) are predicted to decrease the
exposure to duloxetine.oTheoretical
▶ Duloxetine is predicted to increase the exposure to beta
blockers, selective (metoprolol).oStudy
▶ Duloxetine is predicted to increase the exposure to eliglustat.
Avoid or adjust dose—consult product literature.rStudy
▶ HIV-protease inhibitors (ritonavir) are predicted to decrease the
exposure to duloxetine.oTheoretical
▶ Leflunomide is predicted to decrease the exposure to
▶ Duloxetine is predicted to increase the exposure to pitolisant.
Use with caution and adjust dose.oStudy
▶ Quinolones (ciprofloxacin) are predicted to increase the
No comments:
Post a Comment
اكتب تعليق حول الموضوع